ACADIA Pharmaceuticals (ACAD) Q3 2026 earnings summary

Executive summary

• Q3 GAAP revenue was $342.3M, up 23% YoY; adjusted-basis growth was 22%, with DAYBUE and NUPLAZID sales growth.

• Operating income rose to $71.7M from $35.8M; net income declined to $53.5M from $71.8M amid a less favorable tax comparison.

• DAYBUE guidance increased, while RADIANT results informed a 60 mg-focused phase III plan for remlifanserin.

Financial highlights

• Q3 revenue was $342.3M vs. $278.6M GAAP in Q3 2025; compared with adjusted prior-year revenue of $280.9M, growth was 22%.

• DAYBUE net sales were $140.1M vs. $101.1M; NUPLAZID net sales were $202.2M vs. $179.8M adjusted, or $177.5M GAAP.

• R&D expense was $76.3M vs. $87.8M; SG&A was $159.2M vs. $133.4M, reflecting commercial investment and lower spending on completed studies.

• Q3 diluted EPS was $0.31 vs. $0.42; income tax expense was $26.9M vs. a $27.2M tax benefit in Q3 2025.

Outlook and guidance

• FY26 total revenue guidance is $1.265B–$1.295B; DAYBUE global net sales guidance rose to $505M–$520M from $480M–$510M.

• FY26 NUPLAZID net sales guidance is $760M–$775M; gross-to-net guidance is 23%–24% for DAYBUE and 22%–23% for NUPLAZID.

• FY26 R&D expense guidance is $325M–$340M, reduced from $355M–$380M; SG&A guidance is $665M–$685M.

• Phase 2 readouts are expected in 2H 2027 for ACP-211 in MDD and Q4 2027 for remlifanserin in LBDP; ACP-711 essential tremor Phase 2 is expected to begin in 2027.